UAMS - Translational Research Institute

Eligibility

Eligible Ages

Between 18 Years and 79 Years

Eligible Genders

All

Accepts Healthy Volunteers

No

Criteria

Inclusion Criteria:

- Patient must be between 18 and 79 years of age

- Patient must have locoregionally recurrent or second primary HNSCC (oral cavity,
oropharynx, larynx, hypopharynx) in a previously radiated field

- Patient must have undergone surgery with gross total resection and must be randomized
within 8 weeks of surgery

- Patients must have high risk disease defined as:

- Positive margins and/or extra nodal extension (ENE)

- Positive margins are defined as malignancy at or within 1 mm of the margin.
High grade dysplasia (i.e. carcinoma in situ) at the margin is also
considered positive

- ENE may be either gross or microscopic

- Patient must have a PD-L1 Combined Positive Score (CPS) >= 1 in a Clinical Laboratory
Improvement Act (CLIA) certified laboratory. Testing can be done locally as long as it
is done in a CLIA certified laboratory. This testing must be on the tumor specimen
from the resection of the patient's recurrent or second primary HNSCC

- Patient must have had prior radiation to the area of recurrent or second primary
tumor. This is defined as > 50% of the presurgical tumor volume having previously
received a dose of > 45 Gy as determined by the treating radiation oncologist

- Patient must have completed prior radiation a minimum of 6 months prior to
randomization

- Patient must not have any evidence of distant disease based on baseline imaging done
within 28 days prior to randomization

- Patient must not have received anti-PD-1/PD-L1 therapy for recurrent disease. If the
patient received anti-PD-1/PD-L1 therapy as part of initial upfront curative intent
treatment (either as part of definitive non-surgical therapy or in the adjuvant
setting) in the past, the last dosage of anti-PD-1/PD-L1 therapy must have been given
greater than one year prior to randomization

- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1

- Patient must have the ability to understand and the willingness to sign a written
informed consent document. Patients with impaired decision-making capacity (IDMC) who
have a legally authorized representative (LAR) or caregiver and/or family member
available will also be considered eligible

- Patient must not be pregnant or breast-feeding due to the potential harm to an unborn
fetus and possible risk for adverse events in nursing infants with the treatment
regimens being used. All patients of childbearing potential must have a blood test or
urine study within 14 days prior to randomization to rule out pregnancy. A urine or
serum pregnancy test must be repeated within 72 hours prior to receiving the first
dose of pembrolizumab or chemotherapy if the test done for eligibility/randomization
is done outside of this 72 hour window. If the urine test is positive or cannot be
confirmed as negative, a serum pregnancy test will be required. A patient of
childbearing potential is defined as anyone, regardless of sexual orientation or
whether they have undergone tubal ligation, who meets the following criteria: 1) has
achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral
oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer
therapy does not rule out childbearing potential) for at least 24 consecutive months
(i.e., has had menses at any time in the preceding 24 consecutive months)

- Patient must not expect to conceive or father children by using by using accepted and
effective method(s) of contraception or by abstaining from sexual intercourse while on
study treatment, and continue for 120 days after the last dose of study treatment

- Absolute neutrophil count (ANC) >= 1,500/mcL (obtained =< 28 days prior to protocol
randomization)

- Platelets >= 100,000/mcL (obtained =< 28 days prior to protocol randomization)

- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (obtained =< 28
days prior to protocol randomization)

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =<
3.0 x institutional ULN (obtained =< 28 days prior to protocol randomization)

- Creatinine clearance > 30 ml/min using the Cockcroft-Gault formula (obtained =< 28
days prior to protocol randomization)

- Patient must not have a current active infection that requires systemic treatment at
time of randomization

- Patient must not have a history of non-infectious pneumonitis requiring steroids
within 3 years prior to randomization

- Patient must not have a history of solid organ transplant or stem cell transplant

- Patient must not be on immunosuppressive medication within 7 days prior to
randomization, EXCEPT for the following: a) intranasal, inhaled, topical steroids, or
local steroid injection (e.g., intra-articular injection); b) systemic corticosteroids
at physiologic doses =< 10 mg/day of prednisone or equivalent; c) steroids as
premedication for hypersensitivity reactions (e.g., CT scan premedication)

- Patients with known history or current symptoms of cardiac disease, or history of
treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac
function using the New York Heart Association Functional classification. Patients with
New York Heart Association class III or IV heart failure are not eligible

- Patient must not have received a live vaccine within 30 days prior to the first dose
of study drug. Examples of live vaccines include, but are not limited to, the
following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever,
rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza
vaccines for injection are generally killed virus vaccines and are allowed; however,
intranasal influenza vaccines (e.g., FluMist [registered trademark]) are live
attenuated vaccines and are not allowed

- Patient must not have severe hypersensitivity (>= grade 3) to pembrolizumab and/or any
of its excipients

- Patient must not have an active autoimmune disease that has required systemic
treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids
or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or
physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency)
is not considered a form of systemic treatment and is allowed

- Patient must not have a known psychiatric or substance abuse disorder that would
interfere with the participant's ability to cooperate with the requirements of the
study

- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral
therapy with undetectable viral load within 6 months are eligible for this trial as
long as they have not been HIV-infected with a history of Kaposi sarcoma and/or
multicentric Castleman disease

- Patient must not have a known history of hepatitis B (defined as hepatitis B surface
antigen [HBsAg] reactive) or known active hepatitis C virus (defined as HCV
ribonucleic acid [RNA] [qualitative] is detected) infection

- NOTE: No testing for hepatitis B and hepatitis C is required unless mandated by a
local health authority